IDH Mutations in Glioma Patients: From Discovery to Translation to Treatment and Back to Discovery
Needs Statement
Target Audience
Physicians, medical students, fellows, residents, and other health professionals.
Learning Objectives
At the conclusion of the activity, the participants should be able to:
- Identify key mutations in gliomas with an emphasis on the importance of mutations in isocitrate dehydrogenase (IDH).
- Formulate treatment paradigms for neurologic and ocologic aspects of care for patients with IDH-mutant glioma.
- Assess how the discoveries of the IDH mutation in glioma led to translational innovations and treatment innovations for patients with these brain tumors.
Course summary
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Baylor College of Medicine designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Price
Thank you for reviewing this Baylor College of Medicine on-demand activity. In order to complete the evaluation and claim credit for your participation, please select the appropriate payment option above. After payment has been completed, you will receive an email confirmation and receipt.
For any questions, contact [email protected].

Facebook
X
LinkedIn
Forward